V5 Ultimate
Manufacturing

Microbiome, probiotic & postbiotic terminology

Microbiome Supplement Formulation and ISAPP Definitional Discipline · ISAPP postbiotic · synbiotic · strain-level identity · WGS probiotic

TL;DR

Term — microbiome, probiotic and postbiotic definitions: microbiome supplement discipline — ISAPP consensus definitions (probiotic 2014, prebiotic 2017, synbiotic 2020, postbiotic 2021), strain-level identity by whole-genome sequencing with culture collection deposit, antimicrobial resistance gene screening and stability indicator per product type (CFU for probiotic, bioactive marker for postbiotic, substrate retention for prebiotic).

Microbiome supplements span probiotics (live, ISAPP Hill 2014), prebiotics (substrate selectively utilised by host microorganisms with benefit, ISAPP Gibson 2017), synbiotics (probiotic + prebiotic combination with benefit, ISAPP Swanson 2020 with complementary and synergistic sub-types), postbiotics (preparation of inanimate microorganisms or components with benefit, ISAPP Salminen 2021 — excludes purified metabolites without microbial components, purified components without consensus benefit and 'killed probiotic' marketing without measured benefit on the inanimate preparation) and live biotherapeutic products (drug-regulated). Strain-level identity by whole-genome sequencing is the regulatory expectation across FDA, EFSA QPS, Health Canada NHPID, Korea MFDS HFF and Japan FFC — replacing species-level identification because effects are strain-specific. Deposit at recognised culture collection (ATCC, DSMZ, NCIMB, JCM, KCCM, CGMCC) with master cell bank and working cell bank chain of custody. WGS enables antimicrobial resistance gene screening (required EFSA QPS), virulence factor and plasmid characterisation. Stability discipline differs — CFU retention with overage justification and ISO 19344 flow cytometry or USP <61> plate count for probiotics; bioactive marker retention for postbiotics; substrate retention by HPLC for prebiotics (FOS, GOS, inulin, HMOs). EFSA Article 13 has authorised no general 'probiotic' health claim — EU market positioning uses structure/function statements rather than authorised health claims, with cross-market differential copy for US/Japan/Korea.

Regulatory anchors
  • ISAPP Consensus Definitions (Hill 2014, Gibson 2017, Swanson 2020, Salminen 2021)
  • ISO 19344
  • USP <61>
  • EFSA QPS
Industries that live with this
Want to see Microbiome, probiotic & postbiotic terminology in V5?

Free trial, no credit card, onboard in days, not months.